Search

Your search keyword '"Vecchione, Loredana"' showing total 146 results
Start Over Author "Vecchione, Loredana"
146 results on '"Vecchione, Loredana"'

4. A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer

Author

Fernandes Neto, Joao Manuel, primary, Venkatesan, Subramanian, additional, Dias, Matheus, additional, Lieftink, Cor, additional, Morris, Ben, additional, Bresser, Kaspar, additional, Vecchione, Loredana, additional, Evers, Bastiaan, additional, Scheeren, Ferenc, additional, Shumacher, Ton, additional, Beijersbergen, Roderick, additional, and Bernards, Rene, additional

Published
2023
Full Text
View/download PDF

5. Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients—A Single Center Analysis of 2323 Patients within the Last Decade

Author

Neumann, Christopher C. M., primary, Schneider, François, additional, Hilfenhaus, Georg, additional, Vecchione, Loredana, additional, Benzing, Christian, additional, Ihlow, Jana, additional, Fehrenbach, Uli, additional, Malinka, Thomas, additional, Keilholz, Ulrich, additional, Stintzing, Sebastian, additional, and Pelzer, Uwe, additional

Published
2023
Full Text
View/download PDF

6. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Author

Scherr, Anna-Lena, Mock, Andreas, Gdynia, Georg, Schmitt, Nathalie, Heilig, Christoph E., Korell, Felix, Rhadakrishnan, Praveen, Hoffmeister, Paula, Metzeler, Klaus H., Schulze-Osthoff, Klaus, Illert, Anna L., Boerries, Melanie, Trojan, Jörg, Waidmann, Oliver, Falkenhorst, Johanna, Siveke, Jens, Jost, Philipp J., Bitzer, Michael, Malek, Nisar P., Vecchione, Loredana, Jelas, Ivan, Brors, Benedikt, Glimm, Hanno, Stenzinger, Albrecht, Grekova, Svetlana P., Gehrig, Tobias, Schulze-Bergkamen, Henning, Jäger, Dirk, Schirmacher, Peter, Heikenwalder, Mathias, Goeppert, Benjamin, Schneider, Martin, Fröhling, Stefan, and Köhler, Bruno C.

Published
2020
Full Text
View/download PDF

7. Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients—A Single-Center Analysis of 1294 Patients within the Last Decade

Author

Neumann, Christopher C. M., primary, Schneider, François, additional, Hilfenhaus, Georg, additional, Vecchione, Loredana, additional, Felsenstein, Matthäus, additional, Ihlow, Jana, additional, Geisel, Dominik, additional, Sander, Steffen, additional, Pratschke, Johann, additional, Stintzing, Sebastian, additional, Keilholz, Ulrich, additional, and Pelzer, Uwe, additional

Published
2023
Full Text
View/download PDF

8. Supplementary Figure Legends from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Author

Coffee, Erin M., primary, Faber, Anthony C., primary, Roper, Jatin, primary, Sinnamon, Mark J., primary, Goel, Gautam, primary, Keung, Lily, primary, Wang, Wei Vivian, primary, Vecchione, Loredana, primary, de Vriendt, Veerle, primary, Weinstein, Barbara J., primary, Bronson, Roderick T., primary, Tejpar, Sabine, primary, Xavier, Ramnik J., primary, Engelman, Jeffrey A., primary, Martin, Eric S., primary, and Hung, Kenneth E., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Author

Coffee, Erin M., primary, Faber, Anthony C., primary, Roper, Jatin, primary, Sinnamon, Mark J., primary, Goel, Gautam, primary, Keung, Lily, primary, Wang, Wei Vivian, primary, Vecchione, Loredana, primary, de Vriendt, Veerle, primary, Weinstein, Barbara J., primary, Bronson, Roderick T., primary, Tejpar, Sabine, primary, Xavier, Ramnik J., primary, Engelman, Jeffrey A., primary, Martin, Eric S., primary, and Hung, Kenneth E., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 2 from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Author

Coffee, Erin M., primary, Faber, Anthony C., primary, Roper, Jatin, primary, Sinnamon, Mark J., primary, Goel, Gautam, primary, Keung, Lily, primary, Wang, Wei Vivian, primary, Vecchione, Loredana, primary, de Vriendt, Veerle, primary, Weinstein, Barbara J., primary, Bronson, Roderick T., primary, Tejpar, Sabine, primary, Xavier, Ramnik J., primary, Engelman, Jeffrey A., primary, Martin, Eric S., primary, and Hung, Kenneth E., primary

Published
2023
Full Text
View/download PDF

11. Iatrogenic Second Tumors

Author

Lombari, Pietro, Vecchione, Loredana, Farella, Antonio, Grassia, Sebastiano, De Vita, Fernando, Catalano, Giuseppe, Salvatore, Marco, Renda, Andrea, and Renda, Andrea

Published
2009
Full Text
View/download PDF

13. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature

Author

Osumi, Hiroki, primary, Vecchione, Loredana, additional, Keilholz, Ulrich, additional, Vollbrecht, Claudia, additional, Alig, Annabel H.S., additional, von Einem, Jobst C., additional, Stahler, Arndt, additional, Striefler, Jana K., additional, Kurreck, Annika, additional, Kind, Andreas, additional, Modest, Dominik P., additional, Stintzing, Sebastian, additional, and Jelas, Ivan, additional

Published
2021
Full Text
View/download PDF

14. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

Author

Geva, Ravit, Vecchione, Loredana, Kalogeras, Konstantinos T, Jensen, Benny Vittrup, Lenz, Heinz-Josef, Yoshino, Takayuki, Paez, David, Montagut, Clara, Souglakos, John, Cappuzzo, Federico, Cervantes, Andrés, Frattini, Milo, Fountzilas, George, Johansen, Julia S, Høgdall, Estrid Vilma, Zhang, Wu, Yang, Dongyun, Yamazaki, Kentaro, Nishina, Tomohiro, Papamichael, Demetris, Vincenzi, Bruno, Macarulla, Teresa, Loupakis, Fotios, De Schutter, Jef, Spindler, Karen Lise Garm, Pfeiffer, Per, Ciardiello, Fortunato, Piessevaux, Hubert, and Tejpar, Sabine

Published
2015
Full Text
View/download PDF

17. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

Author

Martinelli, Erika, Troiani, Teresa, DʼAiuto, Elena, Morgillo, Floriana, Vitagliano, Donata, Capasso, Anna, Costantino, Sarah, Ciuffreda, Loreta Pia, Merolla, Francesco, Vecchione, Loredana, De Vriendt, Veerle, Tejpar, Sabine, Nappi, Anna, Sforza, Vincenzo, Martini, Giulia, Berrino, Liberato, De Palma, Raffaele, and Ciardiello, Fortunato

Published
2013
Full Text
View/download PDF

20. Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

Author

Schlicker, Andreas, primary, Ellappalayam, Architha, additional, Beumer, Ines J., additional, Snel, Mireille H. J., additional, Mittempergher, Lorenza, additional, Diosdado, Begona, additional, Dreezen, Christa, additional, Tian, Sun, additional, Salazar, Ramon, additional, Loupakis, Fotios, additional, Pietrantonio, Filippo, additional, Santos Vivas, Cristina, additional, Martinez‐Villacampa, Maria Mercedes, additional, Villanueva, Alberto, additional, Sanjuán, Xavier, additional, Schirripa, Marta, additional, Fassan, Matteo, additional, Martinetti, Antonia, additional, Fucà, Giovanni, additional, Lonardi, Sara, additional, Keilholz, Ulrich, additional, Glas, Annuska M., additional, Bernards, René, additional, and Vecchione, Loredana, additional

Published
2020
Full Text
View/download PDF

22. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma

Author

Iolascon Achille, Troncone Giancarlo, Gemei Marica, Montanaro Donatella, Capasso Mario, De Antonellis Pasqualino, Vecchione Loredana, Petrosino Giuseppe, Andolfo Immacolata, Orditura Michele, Ciardiello Fortunato, De Vita Fernando, and Zollo Massimo

Subjects
esophageal carcinoma, cell-free DNA, erbB2 copy number variation, prognostic marker, CTCs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Mortality is high in patients with esophageal carcinoma as tumors are rarely detected before the disease has progressed to an advanced stage. Here, we sought to isolate cell-free DNA released into the plasma of patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early detection of tumor progression. Methods Plasma of 41 patients with esophageal carcinoma was prospectively collected before tumor resection and chemotherapy. Our dataset resulted heterogeneous for clinical data, resembling the characteristics of the tumor. DNA from the plasma was extracted to analyze copy number variations of the erbB2 gene using real-time PCR assays. Results The real-time PCR assays for erbB2 gene showed significant (P = 0.001) copy number variations in the plasma of patients with esophageal carcinoma, as compared to healthy controls with high sensitivity (80%) and specificity (95%). These variations in erbB2 were negatively correlated to the progression free survival of these patients (P = 0.03), and revealed a further risk category stratification of patients with low VEGF expression levels. Conclusion The copy number variation of erbB2 gene from plasma can be used as prognostic marker for early detection of patients at risk of worse clinical outcome in esophageal cancer.

Published
2011
Full Text
View/download PDF

23. Immunotherapy in Gastrointestinal Cancers

Author

Procaccio, Letizia, Schirripa, Marta, Fassan, Matteo, Vecchione, Loredana, Bergamo, Francesca, Prete, Alessandra Anna, Intini, Rossana, Manai, Chiara, Dadduzio, Vincenzo, Boscolo, Alice, Zagonel, Vittorina, and Lonardi, Sara

Subjects
Article Subject
Abstract

Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been reported, a strong biological rationale supports the development of immunotherapy in this field. The clinical and translational research on immunotherapy for the treatment of GI cancers started firstly with the identification of immune-related mechanisms possibly relevant to GI tumours and secondly with the development of immunotherapy-based agents in clinical trials. In the present review a general overview is firstly provided followed by a focus on major findings on gastric, colorectal, and hepatocellular carcinomas. Finally, pathological and molecular perspectives are provided since many efforts are ongoing in order to identify possible predictive biomarkers and to improve patients’ selection. Many issues are still unsolved in this field; however, we strongly believe that immunotherapy might positively affect the natural history of a subgroup of GI cancer patients improving outcome and the overall quality of life.

Published
2017
Full Text
View/download PDF

25. Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients

Author

Vecchione, Loredana, primary, Beumer, Ines, additional, Mulero-Sanchez, Antonio, additional, Snel, Mireille, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Loupakis, Fotios, additional, Martinetti, Antonia, additional, Fuca', Giovanni, additional, Moretto, Roberto, additional, Fontanini, Gabriella, additional, Fassan, Matteo, additional, Lonardi, Sara, additional, Schirripa, Marta, additional, Keilholz, Ulrich, additional, and Bernards, Rene', additional

Published
2018
Full Text
View/download PDF

26. Abstract 206: The Consensus Molecular Classification (CMS) of primary colorectal tumors and their matched liver metastasis: Investigating the concordance

Author

Vecchione, Loredana, primary, Beumer, Ines, additional, Snel, Mireille, additional, Salazar, Ramon, additional, Pietrantonio, Filippo, additional, Loupakis, Fotios, additional, Vivas, Cristina Santos, additional, Martinez-Villacampa, Maria Mercedes, additional, Sanjuan, Xavier, additional, Martinetti, Antonia, additional, Fuca', Giovanni, additional, Schirripa, Marta, additional, Fassan, Matteo, additional, and Bernards, Rene', additional

Published
2018
Full Text
View/download PDF

28. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Author

Vecchione, Loredana, Gambino, Valentina, Raaijmakers, Jonne, Schlicker, Andreas, Fumagalli, Arianna, Russo, Mariangela, Villanueva, Alberto, Beerling, Evelyne, Bartolini, Alice, Mollevi, David G., El-Murr, Nizar, Chiron, Marielle, Calvet, Loreley, Nicolazzi, Céline, Combeau, Cécile, Henry, Christophe, Simon, Iris M., Tian, Sun, In 'T Veld, Sjors, D'Ario, Giovanni, Mainardi, Sara, Beijersbergen, Roderick L., Lieftink, Cor, Linn, Sabine, Rumpf-Kienzl, Cornelia, Delorenzi, Mauro, Wessels, Lodewyk, Salazar, Ramon, Di Nicolantonio, Federica, Bardelli, Alberto, Van Rheenen, Jacco, Medema, René H., Tejpar, Sabine, Bernards, René, Vecchione, Loredana, Gambino, Valentina, Raaijmakers, Jonne, Schlicker, Andreas, Fumagalli, Arianna, Russo, Mariangela, Villanueva, Alberto, Beerling, Evelyne, Bartolini, Alice, Mollevi, David G., El-Murr, Nizar, Chiron, Marielle, Calvet, Loreley, Nicolazzi, Céline, Combeau, Cécile, Henry, Christophe, Simon, Iris M., Tian, Sun, In 'T Veld, Sjors, D'Ario, Giovanni, Mainardi, Sara, Beijersbergen, Roderick L., Lieftink, Cor, Linn, Sabine, Rumpf-Kienzl, Cornelia, Delorenzi, Mauro, Wessels, Lodewyk, Salazar, Ramon, Di Nicolantonio, Federica, Bardelli, Alberto, Van Rheenen, Jacco, Medema, René H., Tejpar, Sabine, and Bernards, René

Published
2016

29. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Author

Hubrecht Institute with UMC, Pathologie, Cancer, UMC Utrecht, CMM Sectie Molecular Cancer Research, CMM USEQ Facility, Vecchione, Loredana, Gambino, Valentina, Raaijmakers, Jonne, Schlicker, Andreas, Fumagalli, Arianna, Russo, Mariangela, Villanueva, Alberto, Beerling, Evelyne, Bartolini, Alice, Mollevi, David G., El-Murr, Nizar, Chiron, Marielle, Calvet, Loreley, Nicolazzi, Céline, Combeau, Cécile, Henry, Christophe, Simon, Iris M., Tian, Sun, In 'T Veld, Sjors, D'Ario, Giovanni, Mainardi, Sara, Beijersbergen, Roderick L., Lieftink, Cor, Linn, Sabine, Rumpf-Kienzl, Cornelia, Delorenzi, Mauro, Wessels, Lodewyk, Salazar, Ramon, Di Nicolantonio, Federica, Bardelli, Alberto, Van Rheenen, Jacco, Medema, René H., Tejpar, Sabine, Bernards, René, Hubrecht Institute with UMC, Pathologie, Cancer, UMC Utrecht, CMM Sectie Molecular Cancer Research, CMM USEQ Facility, Vecchione, Loredana, Gambino, Valentina, Raaijmakers, Jonne, Schlicker, Andreas, Fumagalli, Arianna, Russo, Mariangela, Villanueva, Alberto, Beerling, Evelyne, Bartolini, Alice, Mollevi, David G., El-Murr, Nizar, Chiron, Marielle, Calvet, Loreley, Nicolazzi, Céline, Combeau, Cécile, Henry, Christophe, Simon, Iris M., Tian, Sun, In 'T Veld, Sjors, D'Ario, Giovanni, Mainardi, Sara, Beijersbergen, Roderick L., Lieftink, Cor, Linn, Sabine, Rumpf-Kienzl, Cornelia, Delorenzi, Mauro, Wessels, Lodewyk, Salazar, Ramon, Di Nicolantonio, Federica, Bardelli, Alberto, Van Rheenen, Jacco, Medema, René H., Tejpar, Sabine, and Bernards, René

Published
2016

30. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Author

Vecchione, Loredana, primary, Gambino, Valentina, additional, Raaijmakers, Jonne, additional, Schlicker, Andreas, additional, Fumagalli, Arianna, additional, Russo, Mariangela, additional, Villanueva, Alberto, additional, Beerling, Evelyne, additional, Bartolini, Alice, additional, Mollevi, David G., additional, El-Murr, Nizar, additional, Chiron, Marielle, additional, Calvet, Loreley, additional, Nicolazzi, Céline, additional, Combeau, Cécile, additional, Henry, Christophe, additional, Simon, Iris M., additional, Tian, Sun, additional, in ‘t Veld, Sjors, additional, D’ario, Giovanni, additional, Mainardi, Sara, additional, Beijersbergen, Roderick L., additional, Lieftink, Cor, additional, Linn, Sabine, additional, Rumpf-Kienzl, Cornelia, additional, Delorenzi, Mauro, additional, Wessels, Lodewyk, additional, Salazar, Ramon, additional, Di Nicolantonio, Federica, additional, Bardelli, Alberto, additional, van Rheenen, Jacco, additional, Medema, René H., additional, Tejpar, Sabine, additional, and Bernards, René, additional

Published
2016
Full Text
View/download PDF

31. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

Author

Prahallad, Anirudh, Heynen, Guus J J E, Germano, Giovanni, Willems, Stefan M, Evers, Bastiaan, Vecchione, Loredana, Gambino, Valentina, Lieftink, Cor, Beijersbergen, Roderick L, Di Nicolantonio, Federica, Bardelli, Alberto, Bernards, Rene, Prahallad, Anirudh, Heynen, Guus J J E, Germano, Giovanni, Willems, Stefan M, Evers, Bastiaan, Vecchione, Loredana, Gambino, Valentina, Lieftink, Cor, Beijersbergen, Roderick L, Di Nicolantonio, Federica, Bardelli, Alberto, and Bernards, Rene

Published
2015

32. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

Author

Pathologie Pathologen staf, Other research (not in main researchprogram), Cancer, CMM Sectie Molecular Cancer Research, Prahallad, Anirudh, Heynen, Guus J J E, Germano, Giovanni, Willems, Stefan M, Evers, Bastiaan, Vecchione, Loredana, Gambino, Valentina, Lieftink, Cor, Beijersbergen, Roderick L, Di Nicolantonio, Federica, Bardelli, Alberto, Bernards, Rene, Pathologie Pathologen staf, Other research (not in main researchprogram), Cancer, CMM Sectie Molecular Cancer Research, Prahallad, Anirudh, Heynen, Guus J J E, Germano, Giovanni, Willems, Stefan M, Evers, Bastiaan, Vecchione, Loredana, Gambino, Valentina, Lieftink, Cor, Beijersbergen, Roderick L, Di Nicolantonio, Federica, Bardelli, Alberto, and Bernards, Rene

Published
2015

33. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer:an international consortium study

Author

Geva, Ravit, Vecchione, Loredana, Kalogeras, Konstantinos T, Jensen, Benny Vittrup, Lenz, Heinz-Josef, Yoshino, Takayuki, Paez, David, Montagut, Clara, Souglakos, John, Cappuzzo, Federico, Cervantes, Andrés, Frattini, Milo, Fountzilas, George, Johansen, Julia S, Høgdall, Estrid Vilma, Zhang, Wu, Yang, Dongyun, Yamazaki, Kentaro, Nishina, Tomohiro, Papamichael, Demetris, Vincenzi, Bruno, Macarulla, Teresa, Loupakis, Fotios, De Schutter, Jef, Spindler, Karen Lise Garm, Pfeiffer, Per, Ciardiello, Fortunato, Piessevaux, Hubert, Tejpar, Sabine, Geva, Ravit, Vecchione, Loredana, Kalogeras, Konstantinos T, Jensen, Benny Vittrup, Lenz, Heinz-Josef, Yoshino, Takayuki, Paez, David, Montagut, Clara, Souglakos, John, Cappuzzo, Federico, Cervantes, Andrés, Frattini, Milo, Fountzilas, George, Johansen, Julia S, Høgdall, Estrid Vilma, Zhang, Wu, Yang, Dongyun, Yamazaki, Kentaro, Nishina, Tomohiro, Papamichael, Demetris, Vincenzi, Bruno, Macarulla, Teresa, Loupakis, Fotios, De Schutter, Jef, Spindler, Karen Lise Garm, Pfeiffer, Per, Ciardiello, Fortunato, Piessevaux, Hubert, and Tejpar, Sabine

Abstract

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated with cetuximab alone or in combination with chemotherapy. Fc gamma receptor (FCGR) status was centrally genotyped. Two additional externally genotyped series were included.RESULTS: Incidences of FCGR2A-HH and FCGR3A-VV in KRAS-WT patients were 220/660 (33%) and 109/676 (16.1%) respectively. There was no difference in median PFS (mPFS) for KRAS-WT patients with FCGR2A-HH (22.0 weeks; 95% CI18.8 to 25.2) versus non-HH (22.0 weeks; 95% CI 19.4 to 24.6) or for FCGR3A-VV (16.4 weeks; 95% CI 13.0 to 19.8) versus non-VV (23 weeks; 95% CI 21.1 to 24.9) (p=0.06). Median overall survival, response rate and disease control rate assessments showed no benefit for either HH or VV.CONCLUSIONS: No differences in mPFS were found between the FCGR polymorphisms HH and the others and VV versus the others in KRAS-WT mCRC patients refractory to irinotecan, oxaliplatin and 5-fluorouracil treated with cetuximab. We cannot confirm the effects of other IgG1 antibodies, which may be weaker than previously suggested. Other markers may be needed to study the actual host antibody response to cetuximab.

Published
2015

34. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

Author

Prahallad, Anirudh, primary, Heynen, Guus J.J.E., additional, Germano, Giovanni, additional, Willems, Stefan M., additional, Evers, Bastiaan, additional, Vecchione, Loredana, additional, Gambino, Valentina, additional, Lieftink, Cor, additional, Beijersbergen, Roderick L., additional, Di Nicolantonio, Federica, additional, Bardelli, Alberto, additional, and Bernards, Rene, additional

Published
2015
Full Text
View/download PDF

35. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

Author

Asbagh, Layka Abbasi, primary, Vazquez, Iria, additional, Vecchione, Loredana, additional, Budinska, Eva, additional, De Vriendt, Veerle, additional, Baietti, Maria Francesca, additional, Steklov, Mikhail, additional, Jacobs, Bart, additional, Hoe, Nicholas, additional, Singh, Sharat, additional, Imjeti, Naga-Sailaja, additional, Zimmermann, Pascale, additional, Sablina, Anna, additional, and Tejpar, Sabine, additional

Published
2014
Full Text
View/download PDF

36. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

Author

Geva, Ravit, primary, Vecchione, Loredana, additional, Kalogeras, Konstantinos T, additional, Vittrup Jensen, Benny, additional, Lenz, Heinz-Josef, additional, Yoshino, Takayuki, additional, Paez, David, additional, Montagut, Clara, additional, Souglakos, John, additional, Cappuzzo, Federico, additional, Cervantes, Andrés, additional, Frattini, Milo, additional, Fountzilas, George, additional, Johansen, Julia S, additional, Høgdall, Estrid Vilma, additional, Zhang, Wu, additional, Yang, Dongyun, additional, Yamazaki, Kentaro, additional, Nishina, Tomohiro, additional, Papamichael, Demetris, additional, Vincenzi, Bruno, additional, Macarulla, Teresa, additional, Loupakis, Fotios, additional, De Schutter, Jef, additional, Spindler, Karen Lise Garm, additional, Pfeiffer, Per, additional, Ciardiello, Fortunato, additional, Piessevaux, Hubert, additional, and Tejpar, Sabine, additional

Published
2014
Full Text
View/download PDF

37. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Geva, Ravit, Vecchione, Loredana, Tejpar, Sabine, Piessevaux, Hubert, Van Cutsem, Eric, Prenen, Hans, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Geva, Ravit, Vecchione, Loredana, Tejpar, Sabine, Piessevaux, Hubert, Van Cutsem, Eric, and Prenen, Hans

Abstract

Taking into account the retrospective nature of the study which can influence the selection of patients, bevacizumab given in advanced lines after failure of conventional chemotherapy and antiepidermal growth factor receptor agents can result in high disease control rates in patients with mCRC.

Published
2013

38. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

Author

Geva,Ravit, Vecchione,Loredana, Tejpar,Sabine, Piessevaux,Hubert, Van Cutsem,Eric, Prenen,Hans, Geva,Ravit, Vecchione,Loredana, Tejpar,Sabine, Piessevaux,Hubert, Van Cutsem,Eric, and Prenen,Hans

Abstract

Ravit Geva,1,2 Loredana Vecchione,2 Sabine Tejpar,2 Hubert Piessevaux,3 Eric Van Cutsem,2 Hans Prenen21Gastrointestinal Malignancies Service, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Department of Gastroenterology, Digestive Oncology Unit, University Hospitals Leuven, Leuven, Belgium; 3Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, BelgiumPurpose: The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population.Methods: Forty-six consecutive mCRC patients treated in the University Hospital Gasthuisberg (Leuven, Belgium) receiving bevacizumab in advanced lines following failure of conventional chemotherapy were included in this study. Treatment regimen consisted of bevacizumab 5 mg/kg in combination with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI).Results: Bevacizumab plus chemotherapy was used in third-line treatment in eight (17%) patients and in fourth-line treatment or more in 38 patients (83%). All patients previously failed irinotecan-based chemotherapy, 44 (96%) failed oxaliplatin-based regimens, and 40 (87%) failed treatment with cetuximab. Bevacizumab was given in combination with irinotecan-based chemotherapy in 36 patients, oxaliplatin-based chemotherapy in nine patients, and with single agent 5-fluorouracil in one patient. Objective response was demonstrated in ten patients (22%) and disease control in 38 (83%) with a median progression-free survival of 8.9 months and a median overall survival of 13.8 months. Only four patients exper

Published
2013

39. DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype

Author

De Vriendt, Veerle, primary, De Roock, Wendy, additional, Di Narzo, Antonio Fabio, additional, Tian, Sun, additional, Biesmans, Bart, additional, Jacobs, Bart, additional, Budinska, Eva, additional, Sagaert, Xavier, additional, Rossi, Simona, additional, D’Ario, Giovanni, additional, Delorenzi, Mauro, additional, Simon, Iris, additional, Vecchione, Loredana, additional, and Tejpar, Sabine, additional

Published
2013
Full Text
View/download PDF

48. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Author

Coffee, Erin M., primary, Faber, Anthony C., additional, Roper, Jatin, additional, Sinnamon, Mark J., additional, Goel, Gautam, additional, Keung, Lily, additional, Wang, Wei Vivian, additional, Vecchione, Loredana, additional, de Vriendt, Veerle, additional, Weinstein, Barbara J., additional, Bronson, Roderick T., additional, Tejpar, Sabine, additional, Xavier, Ramnik J., additional, Engelman, Jeffrey A., additional, Martin, Eric S., additional, and Hung, Kenneth E., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results